Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Subst Abuse Treat. 2016 Dec 30;74:65–70. doi: 10.1016/j.jsat.2016.12.010

Table 3.

Reasons for disengagement from OBOT for All Treatment Periods, Treatment Periods ≥1 year and <1 year

Reason All (N=1605)
N (%)
≥1 year-long (N=717)
N (%)
< 1 year (N=888)
N (%)
p-value
Clinic Problems 156 (9.7%) 52 (7.3%) 104 (11.7%) 0.003
Important Life Events 68 (4.2%) 28 (3.9%) 40 (4.5%) 0.56
Health Contraindications 45 (2.8%) 15 (2.1%) 30 (3.4%) 0.11
Relapse 523 (32.6%) 167 (23.3%) 356 (40.1%) <0.0001
Taper 53 (3.3%) 33 (4.6%) 20 (2.3%) 0.01
Legal Issues 62 (3.9%) 20 (2.8%) 42 (4.7%) 0.04
Transfer 86 (5.4%) 40 (5.6%) 46 (5.2%) 0.73
Insurance issues 7 (0.4%) 6 (0.8%) 1 (0.1%) 0.06
Death 0 (0%) 0 (0%) 0 (0%) 0.99
Unknown 492 (30.6%) 162 (22.6%) 330 (37.2%) <0.001
Did Not Disengage 298 (18.6%) 260 (36.3%) 38 (4.3%) <0.0001

Legend: 1) Clinic Problems (e.g. administrative discharge for non-compliance clinic rules or conflict in the patient-provider relationship); 2) Important Life Events (including change in housing, change in social support such as the loss of loved one); 3) Health Contraindications (including medication side effects, significant surgery or pain) 4) Addiction Relapse (with opioids or continued use of other illicit substances, often resulting in the clinic recommending transfer to methadone or detoxification) 5) Taper Off Buprenorphine 6) Transfer (to another buprenorphine or naltrexone clinic) 7) Legal Issues (including incarceration and concern about future incarceration) 8) Insurance or Payment Issues 9) Death- as documented in the medical record 10) Unknown (no reliable or clear documentation of a reason) and 11) Did Not Disengage (still engaged in care at the end of the study period)

p-value based on unadjusted GEE logistic regression models

HHS Vulnerability Disclosure